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A B S T R A C T
Background
Pulmonary arteriovenous malformations are abnormal direct connections between the pulmonary artery and pulmonary vein which
result in a right-to-left shunt. They are associated with substantial morbidity andmortalitymainly from the effects of paradoxical emboli.
Potential complications include stroke, cerebral abscess, pulmonary haemorrhage and hypoxaemia. Embolisation is an endovascular
intervention based on the occlusion of the feeding arteries the pulmonary arteriovenous malformations thus eliminating the abnormal
right-to-left-shunting.
Objectives
To determine the efficacy and safety of embolisation in patients with pulmonary arteriovenous malformations including a comparison
with surgical resection and different embolisation devices.
Search methods
We searched the Cystic Fibrosis and Genetic Disorders Group’s Trials Register; date of last search: 09 February 2012.
We also searched the following databases: the AustralianNewZealandClinical Trials Registry; ClinicalTrials.gov; International Standard
Randomised Controlled Trial Number Register; International Clinical Trials Registry Platform Search Portal (last searched 15 May
2012).
We checked cross-references and searched references from review articles.
Selection criteria
Trials in which individuals with pulmonary arteriovenous malformations were randomly allocated to embolisation compared to no
treatment, surgical resection or embolisation using a different embolisation device.
Data collection and analysis
Studies identified for potential inclusion were independently assessed for eligibility by two authors, with excluded studies further
checked by a third author. No trials were identified for inclusion in the review and hence no analysis was performed.
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Main results
There were no randomised controlled trials identified.
Authors’ conclusions
There is no evidence from randomised controlled trials for embolisation of pulmonary arteriovenous malformations. However, ran-
domised controlled trials are not always feasible on ethical grounds. Accumulated data from observational studies suggest that embolisa-
tion reduces morbidity. A standardised approach to reporting with long-term follow-up through registry studies can help to strengthen
the evidence for embolisation in the absence of randomised controlled trials.
P L A I N L A N G U A G E S U M M A R Y
Embolisation therapy for pulmonary arteriovenous malformations
Pulmonary arteriovenous malformations are abnormal connections between arteries and veins in the lung. They are known to cause
serious complications such as stroke, brain abscess, bleeding in the lung and poor oxygenation. Embolisation is themainstream treatment
for pulmonary arteriovenous malformations. During embolisation, balloon or coil embolisation devices, or both combined, are used
to block the feeding artery or arteries to the pulmonary arteriovenous malformation. These malformations can often be small, multiple
and widely spread out thus not all of them are suitable for embolisation treatment. In this systematic review, we did not identify
any randomised controlled trials of embolisation versus surgery or comparing different embolisation devices. While accumulated
observational studies have suggested benefits of embolisation, randomised controlled trials are not always feasible on ethical grounds.
In the absence of randomised controlled trials, a standardised approach to reporting, as well as long-term follow-up through registry
studies can help to improve the safety and outcome of embolisation for pulmonary arteriovenous malformations.
B A C K G R O U N D
Description of the condition
Pulmonary arteriovenous malformations (PAVMs) are abnormal
direct connections between a pulmonary artery and a pulmonary
vein. The malformations can manifest as a single focal lesion or as
multiple lesions. It is estimated that about 90% of individuals with
PAVMs have hereditary haemorrhagic telangiectasia (HHT) and
only about 50% of individuals with HHT have PAVMs (Cottin
2004; Shovlin 2008a). Therefore, individuals with PAVMs who
have not been previously diagnosed with HHT should be tested
for the genetic disorder (Shovlin 2008a). The incidence of PAVMs
is 1 per 100 000 population with a male to female ratio ranging
from 1:1.5 to 1.8 (Abdalla 2006; Khurshid 2002). A large propor-
tion (83%) of PAVMs involves the lower lung zones, with involve-
ment of upper lung zones seen in 17%of individuals (Remy-Jardin
2006). A smaller subset of individuals with PAVMs has a more
severe and diffuse pattern of disease which is defined as PAVMs
involving every segmental or every subsegmental artery of at least
one lobe or most recently re-defined as PAVMs involvement of
a single segmental artery rather than a whole lobe (Faughnan
2000; Pierucci 2008). The distribution of diffuse PAVMs aremore
commonly bilateral (72%) rather than unilateral (28%) (Pierucci
2008); and they are described as being either simple or complex. A
simple PAVM is supplied by one artery, whereas the complex va-
riety receives blood supply from two or more arteries. Non HHT-
related PAVMs are most commonly sporadic, or secondary to
hepato-pulmonary syndrome, caval pulmonary shunts, or trauma
(Shovlin 2010).
The approximate prevalence rate of HHT, which is an autoso-
mal dominant disorder, is estimated to be 1 in 50,000 to 80,000
(Dakeishi 2002;Kjeldsen1999). IndividualswithHHThavemul-
tiorgan vascular dysplasia, the tendency to formblood vessels with-
out intervening capillaries between an artery and a vein. The con-
nection segment between an artery and a vein tends to be frag-
ile and can rupture and bleed. The affected small blood vessel is
termed telangiectasia and the affected larger blood vessel is termed
arteriovenousmalformation (AVM). Suchmalformations inHHT
are only occasionally congenital; most develop during puberty. In
1999, the Scientific Advisory Board of the HHT Foundation In-
ternational Incorporated established clinical criteria for the diag-
nosis of HHT known as the Curaςao criteria (Shovlin 2000). Di-
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agnosis of HHT is definite if three criteria are present. A diagnosis
of HHT cannot be established in people with only two criteria;
however, a high index of clinical suspicion should bemaintained. A
diagnosis of HHT is unlikely if fewer than two criteria are present.
The Curaςao criteria are as follows:
1. epistaxis - spontaneous, recurrent nosebleeds;
2. telangiectases - at characteristic sites (lips, oral cavity,
fingers, nose);
3. visceral lesions - such as gastrointestinal telangiectasia (with
or without bleeding), pulmonary AVM, hepatic AVM, cerebral
AVM, spinal AVM;
4. family history - a first-degree relative with HHT.
Most people with PAVMs are identified as having HHT if it is
screened for carefully (Bayrak-Toydemir 2004). A genetically het-
erogeneous disorder, several subtypes of HHT have been identi-
fied including: HHT type 1 associated with ENG gene mutation
encoding endoglin on chromosome 9 and HHT type 2 associated
with ACVRL1 gene mutation (activin receptor-like kinase1) en-
coding activin receptor-like kinase (ALK-1) on chromosome 12
(Abdalla 2006). A subset of people with HHT is associated with
juvenile polyposis (JPHT) and harbours mutations in the SMAD4
gene encoding Smad 4 on chromosome 18 (Gallione 2004). There
are at least two further unidentified genes that can cause classical
HHT mapped to chromosome 5q (HHT type 3) and chromo-
some 7p (HHT type 4) (Govani 2009). The majority of HHT pa-
tients (over 80%) will have mutations in either ENG or ACVRL1
(Gallione 2004).
Description of the intervention
Currently, embolisation is the most commonly used treatment for
people with PAVMs. The advantages of embolisation over surgical
intervention of PAVMs are that it is less invasive and easy to repeat.
The three major indications for treatment include:
1. prevention of neurological complications including stroke
and cerebral abscess (Shovlin 2008a);
2. improvement in exercise tolerance (Gupta 2002);
3. prevention of lung haemorrhage.
The radiological literature currently advocates embolisation to be
offered to both symptomatic patients and asymptomatic patients
with PAVMs of a size amenable to embolisation. In the past, some
institutions considered PAVMs of 3 mm as a threshold for emboli-
sation; however, such recommendations were withdrawn in 2006
with suggestions that smaller PAVMs may benefit from embolisa-
tion. Treatment of PAVMs less than 3 mm in size has the benefit
of protection against bacterial embolisation as well as paradoxic
bland embolisation (Pollak 2006).Moreover, smaller PAVMs have
the potential to enlarge over time (Pollak 2006; Shovlin 2008a).
However, embolisation of smaller vessels is technically difficult be-
cause they are harder to cannulate, and this may result in occlusion
of larger proximal vessels.
The embolisation procedure is performed by an interventional ra-
diologist. There are variations in practice regarding the use of an-
tibiotic prophylaxis before catheter-directed embolisation, which
has the potential to produce bacteraemia (Borrero 2006; Shovlin
2008a). A right femoral venous puncture is used and a catheter is
directed into the right and then left pulmonary arteries. The initial
angiograms of each side provide a general overview of the number
and distribution of PAVMs. During embolisation of PAVMs, the
target is the supplying artery immediately preceding the aneurys-
mal sac. The use of coaxial catheters allows precise placement of
the embolisation device and is critical to the outcome of the pro-
cedure (White 2007). In the co-axial catheter, the outer or guide
catheter, is essential for stable placement while the inner catheter
is used for deployment of embolisation device. Once the emboli-
sation device is securely in place, angiography is repeated to de-
termine whether all possible conduits to the aneurysmal sac have
been occluded.
How the intervention might work
The choice of embolisation device depends on the vascular
anatomy of the individual. In general, PAVMs with feeding artery
diameters of 3 to 9 mm are treated with either balloons or coils
and those with feeding artery diameters greater than 8 mm are
treated with coils alone or with an over-inflated balloon impacted
within a nest of coils (Lee 1997; Saluja 1999).
Types of embolisation device:
1. coil (various types of fibered and unfibered, detachable, and
pushable coils);
2. detachable balloon;
3. amplatzer vascular plugs, most recent device (Ferro 2007)
The deployed coils are designed to coil within the vessel lumen
and carry microfibres which activate platelets to generate an oc-
cluding platelet plug, while amplatzer and balloon devices provide
direct obstruction to vascular flow. Balloon embolisation offers an
additional advantage in that balloon inflation, placement, and lo-
cation may be adjusted before detachment of the device (Borrero
2006).The most recent embolisation device on the market is the
amplatzer vascular plug. This self-expanding cylindrical mesh cage
allows a chance of recapture and redeployment until proper posi-
tioning is achieved (Ferro 2007). The choice of embolisation de-
vice is operator-dependent and correct angiographic assessment
of vessel size can prevent device-associated complications such as
down-stream migration of the device.
Since embolisation became standard practice in the 1980s, surgi-
cal resection of PAVMs has largely been reserved for PAVMs not
amenable to embolisation. Surgery is also used as an emergency
procedure to control haemorrhage, when loss of lung tissue is justi-
fied. Available surgical techniques include different extent of surgi-
cal excision of PAVMs: local excision; segmental resection; lobec-
tomy; ligation; and even pneumonectomy, but whenever possible
lung conservation resection is the preferred choice of treatment.
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It is important to emphasise that the majority of individuals with
PAVMs do not have disease suitable for surgery because the size
and diffuse distribution of PAVMs. Chest computed tomography
(CT) studies indicate that fewer than one third of patients have
single PAVMs, and at least 60% to 70% have residual PAVMs too
small for embolization (Shovlin 2010). Hence any study compar-
ing surgical resection of PAVMs with embolisation will be feasible
only in a small selective portion of people with solitary PAVM and
without evidence of PAVMs elsewhere.
Neither embolisation nor surgery will completely eradicate
PAVMs in people withHHT, as small PAVMsmay persist and new
PAVMsmay be formed. On the other hand, shunting can be abol-
ished even in people with HHT if large PAVMs are treated. The
majority of patients have small shunts. Hence, the use of antibiotic
prophylaxis in interventional procedures such as embolisation and
dental procedures is still recommended (Borrero 2006; Shovlin
2008a). Embolisation and surgery for PAVMs both require spe-
cialised techniques and experience. Procedure complications are
operator-dependent and are related to the number of procedures
performed annually (Hannan 1989). Since HHT is a multi-organ
disease, it is best managed in specialised HHT centres with high-
volume experience as well as access to multidisciplinary experts.
Why it is important to do this review
Although the natural history of untreated PAVMs has not
been optimally defined, data from observational studies of un-
treated PAVMs cases demonstrate considerable morbidity in-
cluding stroke, cerebral abscess, hypoxaemia and haemorrhage
(Faughnan 2000; Pollak 2006). Mortality is considered to be
caused by PAVMs if death is due to cerebral abscess, stroke,
haemoptysis or haemothorax. A study on the prevalence and mor-
tality of HHT in a Danish population found increased mortality,
most pronounced amongst those below the age of 60 years, with
severe gastrointestinal bleeding and history of untreated PAVMs
causing respiratory symptoms as contributor to death (Kjeldsen
1999). A life-expectancy study by Sabbà of 70 people with HHT
also showed a decrease in average lifespan of HHT patients com-
pared to a control group, with a reduction of life expectancy ap-
proaching 6.8 years. A double peak for mortality was observed
with an early peak in the under-50s and a late peak in the 60 to
79 year age group, which can be attributed to major acute compli-
cations and chronic organ involvement (Sabbà 2006). The study
also highlighted the potential for maternal complications with the
deaths of two young women during childbirth, due to haemor-
rhage from PAVMs and cerebral AVMs (Sabbà 2006). A cohort
study by Shovlin provides the first quantification of maternal com-
plications of pregnancy in 111 women with HHT and PAVMs.
The study showed that 1.0% of pregnancies resulted in a major
pulmonary haemorrhage from the PAVMs; 1.2% in stroke (not all
wereHHT-related); and 1.0% inmaternal death (Shovlin 2008c).
The current practice recommends embolisation of all PAVMs in
the absence of contraindications such as severe pulmonary hy-
pertension, renal failure, and early pregnancy. In 2008, a cohort
study by Shovlin concluded that it is difficult to predict which
HHT patients are at risk of PAVMs complications with refer-
ence to PAVMs size, severity and symptoms (Shovlin 2008a). The
study suggested the need for greater emphasis on HHT diagno-
sis, PAVMs screening and the necessity of implementing PAVMs
treatment programmes (Shovlin 2008a). This systematic review
will provide an overview of the available evidence from the liter-
ature and will show the strength of evidence available in order to
make recommendations for current practice and future research.
O B J E C T I V E S
To establish if embolisation is a safe and effective procedure for
pulmonary arteriovenous malformations compared to no inter-
vention, as well as a comparison of different embolisation devices.
We also planned to include RCTs which compare surgical resec-
tion of PAVMs with embolisation. This will be feasible in a small
selective portion of patients with single PAVM and without evi-
dence of PAVMs elsewhere.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised and quasi-randomised controlled trials.
Types of participants
Participants of all ages with PAVMs with feeding arteries that are
determined to be suitable for embolisation. Individuals with both
simple and complex PAVMs are included in the review.
Types of interventions
Embolisation techniques compared to no treatment or compari-
son of two different embolisation devices. Comparisions of em-
bolisation to surgical resection of PAVMs are included as emer-
gency procedures.
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Types of outcome measures
Primary outcomes
1. Initial occlusion as determined by angiogram immediately
after embolisation
2. Long-term occlusion as determined by
i) chest radiography (standard posteroanterior and lateral
chest radiographs)
ii) contrast “bubble” echocardiography
iii) radionuclide shunt study and pulse oximetry (SaO2)
a) measured in up-right position
b) measured in supine position
iv) computed tomography (CT)
a) helical CT pulmonary angiogram with 3D
reconstruction for assessment of PAVM perfusion (post hoc
change)
b) helical CT without contrast media for assessment
of PAVM morphology only
3. All causes mortality secondary to PAVM if death was due to
any cause, including:
i) cerebral abscess
ii) stroke
iii) haemoptysis
iv) haemothorax
Secondary outcomes
1. Exercise capacity (comparison with data obtained prior to
embolisation)
i) any recognised and reproducible exercise test e.g. 6-
minutes walk test
2. Pulmonary function tests (comparison with data prior to
embolisation)
i) forced expiratory volume in one second (FEV1)
ii) vital capacity
iii) single-breath diffusing capacity for carbon monoxide
(D LCO )
iv) diffusing capacity for carbon monoxide per unit of
alveolar volume (KCO[DL/VA]
3. Adverse events
i) device-related complications (e.g. vascular perforation,
intramural arterial dissection, myocardial rupture, device
migration, early deflation of balloon, and paradoxical balloon or
coil embolisation at the time of deployment)
ii) procedure-related complications (e.g. pulmonary
infarction, pulmonary hypertension, cardiac arrhythmias,
thrombophlebitis and deep venous thrombosis and those related
to the venous puncture, such as a haematoma, transient
symptoms (angina, confusion, bradycardia, and perioral
paraesthesias), transient ischaemic attacks and cerebrovascular
accident
Search methods for identification of studies
Electronic searches
Using the term ’hereditary haemorrhagic telangiectasia’, we
searched for relevant trials from the Cystic Fibrosis and Ge-
netic Disorders Group’s Trials Registers, compiled from electronic
searches of the Cochrane Central Register of Controlled Trials
(CENTRAL) (updated with each new issue of The Cochrane Li-
brary), and quarterly searches of MEDLINE. For details of hand
searching, please see the appropriate sections of the Cystic Fibrosis
and Genetic Disorders Group’s Module.
Latest search of the Group’s Trials Register (searched for all years
without limitations): 09 February 2012.
The search strategies forThe Cochrane Library andMEDLINE are
presented in the appendices (Appendix 1; Appendix 2). Date of
the last search of these databases: 09 February 2012.
We also searched the international registers of clinical trials
in the following databases for all years without limitations.
Searched terms used “pulmonary arteriovenous malformation(s)”
or “PAVM(s)”.
• Australian and New Zealand Clinical Trials Registry;
• Clinicaltrials.gov;
• International Standard Randomised Controlled Trial
Number Register;
• International Clinical Trials Registry Platform Search
Portal.
Latest search date: 15 May 2012.
Searching other resources
In the initial review we contacted medical equipment manufac-
turers of embolisation devices (Cook Medical and AGA Medi-
cal Cooporation, manufacturers of Amplatzer Vascular Plug) and
specialised HHTCenters listed by the Osler-Weber-Rendu-HHT
Foundation International by email, to identify any unpublished
trials. We made no further contacts for the subsequent update of
the review in 2012.
We scrutinized references used in the review and identified in the
searches for possible published articles.
Data collection and analysis
Since no trials were included in the review, we were unable to carry
out any analysis. For future updates, when studies are identified
for inclusion in the review, we will apply the following methods.
Selection of studies
Two authors (CC-THandGNCK) independently assessed studies
identified for inclusion in the reviewusing the criteria stated above.
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When there were disagreements, the third author (SAT) acted as
arbiter.
Data extraction and management
Two authors (CC-TH and GNCK) will independently extract
data from the studies included in the review using a standard
data extraction form. If there are disagreements, the third author
(SAT) will act as arbiter. They will assess outcome measures at
time intervals as follows: primary outcomes concerning long-term
occlusions, adverse events; and all secondary outcomes measures
will be assessed at intervals up to three months, up to six months,
up to one year and annually thereafter. If different time points are
reported, they will also consider these.
Assessment of risk of bias in included studies
Three authors (CC-TH, GNCK and MLvD) will assess the risk
of bias for each study as described in the Cochrane Handbook for
Systematic Reviews of Interventions 5.1 (Higgins 2011) for each of
the following domains:
1. randomisation;
2. allocation concealment;
3. blinding (of participants, personnel and outcome assessors);
4. completeness of data;
5. selective outcome reporting;
6. other sources of bias.
Measures of treatment effect
When dealing with dichotomous outcome measures, the authors
will calculate a pooled estimate of the treatment effect for each out-
come across trials using the odds ratio (OR) (the odds of an out-
come among treatment allocated participants to the correspond-
ing odds among controls) and the 95% confidence intervals (CIs).
For continuous outcomes, they plan to record either the mean
change from baseline for each group or the mean post-interven-
tion values and standard deviations for each group. Then, where
appropriate, they plan to calculate a pooled estimate of treatment
effect by calculating the mean difference and 95% CIs.
Unit of analysis issues
Cross-over trials are not included in the review because there is
only a single treatment designated to each group. If treatment by
embolisation is successful, it is inappropriate to expose participants
to other forms of intervention, i.e. surgery.
Dealing with missing data
In order to allow an intention-to-treat analysis, the authors plan
to seek data on the number of participants with each outcome
event by allocated treatment group, irrespective of compliance and
whether or not the participant was later thought to be ineligible or
otherwise excluded from the treatment or follow up. The review
authors will request any missing data from the original investiga-
tors if appropriate.
Assessment of heterogeneity
The authors plan to assess statistical heterogeneity in the meta-
analysis using the I2 statistic (Higgins 2011) and explore reasons
for heterogeneity. Thresholds for the interpretation of I2 can be
misleading, since the importance of inconsistency depends on sev-
eral factors. The authors plan to use the rough guide to interpreta-
tion as outlined in the Cochrane Handbook for Systematic Reviews
of Interventions 5.1 (Higgins 2011).
Assessment of reporting biases
The authors will investigate publication bias using funnel plots if
10 or more studies are identified.
Data synthesis
The authors plan to use a fixed-effect model in their analysis. If
they identify heterogeneity (I2 greater than 50%), they will assess
the significance of the treatment effect by using a random-effects
model.
Subgroup analysis and investigation of heterogeneity
The authors plan the following subgroup analyses if 10 or more
studies are identified, with participants stratified by the following
factors:
1. embolisation materials;
i) coil (various types of fibered and unfibered,
detachable, and pushable coils)
ii) detachable balloon embolisation
iii) amplatzer vascular plugs
2. emergency treatments of PAVMs - surgical resection versus
embolisation;
3. simple versus complex PAVMs;
4. children (up to 18 years) versus adults (18 years and over).
Sensitivity analysis
The authors plan to undertake sensitivity analysis where only trials
with adequate allocation concealment and blinding (low risk of
bias) are included.
R E S U L T S
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Description of studies
See: Characteristics of excluded studies.
Results of the search
The search of the Cystic Fibrosis and Genetic Disorders Review
Group’s Trials Registers did not identify any relevant trials. There
were also no trials identified from searches of the ongoing trials
databases.
The search of The Cochrane Library did not identify any trials rel-
evant to the topic. The MEDLINE searches yield did not iden-
tify any RCTs, however, nine observational studies relevant to the
topic were classified as excluded studies. Cross-referencing failed
to identified any RCTs; 17 observational studies relevant to the
topic were identified. This includes nine prospective case series
listed in Characteristics of excluded studies and 17 retrospective
case reviews included in the Additional references.
We contacted the following medical equipment manufacturers of
embolisation devices by email, to identify any unpublished trials,
but have not yet received a response:
• Cook Medical (contacted 14 November 2009);
• AGA Medical Cooporation, manufacturers of Amplatzer
Vascular Plug (contacted 14 November 2009).
We contacted the specialised HHT Centers listed by the Osler-
Weber-Rendu-HHTFoundation International by email for results
of unpublished clinical studies. Twelve centres responded, with no
RCTs identified.
• HHT Center Israel Schneider Children’s Medical Center of
Israel Rabin Medical Center, Tel Aviv University (replied 14
December 2009): no RCTs identified.
• HHT Center Norway, Rikshospitalet University Hospital
(replied 9 December 2009): no RCTs identified.
• The Institute of Vascular Interventional Radiology, The
First Affiliated Hospital of China Medical University (replied 8
December 2009): no RCTs identified.
• National HHT Centre Ireland, Mercy University Hospital
(replied 6 December 2009): no RCTs identified.
• HHT Center Spain, Hospital Sierrallana (Servicio Cantabro
de Salud) (replied 4 December 2009): no RCTs identified.
• HHT Germany-Marburg, Philipps-University (replied 4
December 2009): no RCTs identified.
• HHT Germany-Cologne, Holweide Hospital (replied 2
December 2009): no RCTs identified.
• HHT Germany-Lippspringe, Karl-Hansen Medical Center
(replied 2 December 2009): no RCTs identified.
• HHT London, Hammersmith Hospital (replied 27
November 2009): no RCTs identified.
• Edmonton HHT Center (replied 25 November 2009): no
RCTs identified.
• Washington University School of Medicine (replied 22
November 2009): no RCTs identified.
• Medical College of Georgia HHT Center (replied 19
November 2009): no RCTs identified
Included studies
No randomised controlled trials have been identified which are
eligible for inclusion in the review.
Excluded studies
The studies listed under ’Characteristics of excluded studies’ were
not eligible for inclusion because they were neither randomised
and quasi-randomised controlled trials (Dutton 1995; Gupta
2002; Haitjema 1995; Lacombe 2009; Liu 2010; Pollak 1994;
Pollak 2006; Shovlin 2008a; Shovlin 2008b).
Seventeen studies were retrospective case reviews which we did
not feel should be listed as ’Excluded studies’, but we have listed
these in the Additional references section for completeness (Brillet
2007; Cil 2008; Curie 2007; Faughnan 2000; Faughnan 2004; Lee
1997; Mager 2004; Pierucci 2008; Post 2006; Prasad 2004; Remy
1992; Remy-Jardin 2006; Sagara 1998; Saluja 1999; Swanson
1999; White 1983; White 1988).
Risk of bias in included studies
There are no included studies.
Effects of interventions
Noeligible studies for inclusion in this reviewhave been identified.
D I S C U S S I O N
Summary of main results
Pulmonary arteriovenousmalformation (PAVM) can cause serious
neurologic complications (stroke, cerebral abscess), pulmonary
haemorrhage and hypoxaemia. The prognosis from historical un-
treated individuals suggests substantial mortality and morbidity.
Overall, approximately 33% of individuals with PAVM will have
a history of stroke, 18% of transient ischaemic attack (TIA), 23%
of cerebral abscess, 3% of haemothorax and 59% with symptoms
of dyspnoea or exercise intolerance (Pollak 2006). A recent pub-
lication concluded that HHT cerebral abscesses are strongly asso-
ciated with PAVM and anaerobic germs and early detection and
treatment may avoid recurrence (Mathis 2012).
Embolisation has become mainstream treatment for PAVMs since
it was introduced in the 1980s. It is less invasive and may reduce
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the risks associated with the original standard surgical treatment.
Despite this, we did not find any evidence from RCTs or CCTs
assessing the role of embolisation in the management of PAVMs.
We excluded 25 observational studies, this number includes nine
prospective case series (see Characteristics of excluded studies) and
17 retrospective case reviews (see Additional references).
Agreements and disagreements with other
studies or reviews
Todate no experimental studies (i.e. RCTs) have supported the fact
that embolisation has become mainstream treatment for PAVMs.
Information on the effectiveness of the procedure and proce-
dure-related complications is only available from non-controlled,
mostly retrospective observational case series.These studies have a
high risk of bias, e.g. a biased selection of participants, recall bias
due to poor reporting in medical records, and ascertainment bias
(Higgins 2011).
A retrospective study by Remy-Jardin evaluated the long-term ef-
fectiveness of coil embolisation (38 individuals with 64 PAVMs)
over approximately 10 years (Remy-Jardin 2006). Follow-up with
CT imaging showed a long-term success rate of 75%; treat-
ment failure was attributed to recanalisation of the occluded feed-
ing artery, previously unrecognised additional feeding arteries of
complex PAVMs and development of systemic perfusion of the
aneurysmal sac (Remy-Jardin 2006). A prospective study by Pol-
lack using embolisation (415 PAVMs in 155 individuals) empha-
sised the need for both clinical follow-up and imaging evaluation
after embolisation when problems related to PAVMs occurred in
23% of individuals and residual lesions were detected by CT imag-
ing in 2.8% of patients. In addition, CT detected enlargement
of previous small PAVMs in 18% of individuals, many of whom
were asymptomatic (Pollak 2006).
A prospective study by Shovlin (323 individuals with HHT and
PAVMs, median age 45 years) provides the strongest evidence to
date showing a significant reduction in the rate of ischaemic stroke
following embolisation. However, strokes and brain abscesses oc-
curred in some individuals with small untreatable PAVMs, de-
spite other existing PAVMs having been treated by embolisation
(Shovlin 2008a). The benefits of embolisation also extended to
those with diffuse pattern of disease with two retrospective reviews
suggesting reduction of neurological complications after successful
embolisation in most patients (Faughnan 2000; Lacombe 2009).
The post-embolisation morbidity and mortality can also be at-
tributed to reperfusion of embolised PAVMs or enlargement of
non-embolised PAVMs (Lacombe 2009).
Complications (such as cerebral infarction, chest pain or device-
related complications) resulting from embolisation in the excluded
observational studies appear to be limited (Lee 1997;Mager 2004;
Pollak 2006). A retrospective study showed that embolisation of
PAVMs did not lead to a consistent increase in resting pulmonary
artery pressure in a series which excluded individuals with severe
pulmonary arterial hypertension (Shovlin 2008b). In rare cases,
massive haemoptysis has been reported at follow-up post emboli-
sation (Pierucci 2008; Sagara 1998). These can be attributed to the
development of bronchial feeding arteries to embolised PAVM.
Evidence suggests that PAVM can occur early in life and present
with serious life-threatening complications; however, there are cur-
rently only a limited number of observational studies available
on embolisation for PAVM in children (Curie 2007; Faughnan
2004). There is only limited evidence from observational stud-
ies that children can benefit from embolisation with success and
complication rates comparable to adults.
Evidence from observational data only without any comparison
to a control group cannot determine if embolisation is the most
effective treatment for PAVM.However, given the fact that expos-
ing patients to potentially more harmful procedures (i.e. surgical
removal of the PAVM) in a RCT would be undesirable for ethical
reasons, it is unlikely that high-level evidence will become avail-
able in the near future. In order to strengthen the evidence base for
embolisation, a standardised approach to reporting patient charac-
teristics, co-morbidity (and any other potential confounders) and
procedures, as well as long-term follow-up protocols are needed.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Embolisation of PAVMs is a minimally invasive procedure which
avoids risks associated with general anaesthesia and minimises the
loss of pulmonary parenchyma in lung resection surgery. There are
no RCTs evidence of embolisation of PAVMs and the current ev-
idence for embolisation is based on retrospective and prospective
studies. Results from these observational studies suggest a substan-
tial reduction in mortality and morbidity. The procedure and de-
vice complication rates have been minimal, however serious com-
plications include precipitation of pulmonary hypertension and
massive haemoptysis. Current recommendations based on obser-
vational studies suggest that all PAVMs amenable to embolisation
should be treated and that surgery is to be reserved for individuals
with PAVMs that are not amenable to embolisation.
Implications for research
It is not always feasible to undertake RCTs on ethical grounds
as accumulated evidence from observational studies suggests that
embolisation of PAVMs result in substantial reductions in mortal-
ity and morbidity. Future RCTs maybe feasible to compare differ-
ent embolisation devices or techniques. In the absence of RCTs,
we suggest a standardised approach to reporting, as well as long-
term follow-up through registry studies to help improve the safety
and outcome of embolisation for PAVMs.
8Embolisation for pulmonary arteriovenous malformation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A C K N OW L E D G E M E N T S
We would like to thank Nikki Jahnke, Managing Editor of the
Cochrane Cystic Fibrosis and Genetic Disorders Group for her
support. We would also like to thank Dr Claire Shovlin for pro-
viding an in-depth peer review.
R E F E R E N C E S
References to studies excluded from this review
Dutton 1995 {published data only}
Dutton JA, Jackson JE, Hughes JM,Whyte MK, Peters AM,
Ussov W, et al.Pulmonary arteriovenous malformations:
results of treatment with coil embolization in 53 patients.
American Journal of Roentgenology 1995;165(5):1119–25.
Gupta 2002 {published data only}
Gupta P, Mordin C, Curtis J, Hughes JM, Shovlin CL,
Jackson JE. Pulmonary arteriovenous malformations: effect
of embolization on right-to-left shunt, hypoxemia, and
exercise tolerance in 66 patients. American Journal of
Roentgenology 2002;179(2):347–55.
Haitjema 1995 {published data only}
Haitjema TJ, Overtoom TT, Westermann CJ, Lammers JW.
Embolisation of pulmonary arteriovenous malformations:
results and follow up in 32 patients. Thorax 1995;50(7):
719–23.
Lacombe 2009 {published data only}
Lacombe P, Lagrange C, Beauchet A, El Hajjam M,
Chinet T, Pelage JP. Diffuse pulmonary arteriovenous
malformations in hereditary hemorrhagic telangiectasia:
long-term results of embolization according to the extent of
lung involvement. Chest 2009;135(4):1031–7.
Liu 2010 {published data only}
Liu FY, Wang MQ, Fan QS, Duan F, Wang ZJ, Song P.
Endovascular embolization of pulmonary arteriovenous
malformations. Chinese Medical Journal 2010;123(1):23–8.
Pollak 1994 {published data only}
Pollak JS, Egglin TK, Rosenblatt MM, Dickey KW,
White RI Jr. Clinical results of transvenous systemic
embolotherapy with a neuroradiologic detachable balloon.
Radiology 1994;191(2):477–82.
Pollak 2006 {published data only}
Pollak JS, Saluja S, Thabet A, Henderson KJ, Denbow
N, White RI Jr. Clinical and anatomic outcomes after
embolotherapy of pulmonary arteriovenous malformations.
Journal of Vascular and Interventional Radiology 2006;17(1):
35–45.
Shovlin 2008a {published data only}
Shovlin CL, Jackson JE, Bamford KB, Jenkins IH, Benjamin
AR, Ramadan H, et al.Primary determinants of ischaemic
stroke/brain abscess risks are independent of severity of
pulmonary arteriovenous malformations in hereditary
haemorrhagic telangiectasia. Thorax 2008;63(3):259–66.
Shovlin 2008b {published data only}
Shovlin CL, Tighe HC, Davies RJ, Gibbs JS, Jackson JE.
Embolisation of pulmonary arteriovenous malformations:
no consistent effect on pulmonary artery pressure. European
Respiratory Journal 2008;32(1):162–9.
Additional references
Abdalla 2006
Abdalla SA, Letarte M. Hereditary haemorrhagic
telangiectasia: current views on genetics and mechanisms of
disease. Journal of Medical Genetics 2006;43(2):97–110.
Bayrak-Toydemir 2004
Bayrak-Toydemir P, Mao R, Lewin S, McDonald J.
Hereditary hemorrhagic telangiectasia: an overview of
diagnosis and management in the molecular era for
clinicians. Genetics in Medicine 2004;6(4):175–91.
Borrero 2006
Borrero CG, Zajko AB. Pulmonary arteriovenous
malformations: clinical Features, diagnosis, and treatment.
Journal of Radiology Nursing 2006;25(2):33–7.
Brillet 2007
Brillet PY, Dumont P, Bouaziz N, Duhamel A, Laurent
F, Remy J, et al.Pulmonary arteriovenous malformation
treated with embolotherapy: systemic collateral supply at
multidetector CT angiography after 2-20-year follow-up.
Radiology 2007;242(1):267–76.
Cil 2008
Cil B, Peynircio lu B, Canyi it M, Geyik S, Ciftçi T.
Peripheral vascular applications of the Amplatzer vascular
plug. Diagnostic and Interventional Radiology 2008;14(1):
35–9.
Cottin 2004
Cottin V, Plauchu H, Bayle JY, Barthelet M, Revel D,
Cordier JF. Pulmonary arteriovenous malformations
in patients with hereditary hemorrhagic telangiectasia.
American Journal of Respiratory Criticial Care Medicine
2004;169(9):994–1000.
Curie 2007
Curie A, Lesca G, Cottin V, Edery P, Bellon G, Faughnan
ME, et al.Long-term follow-up in 12 children with
pulmonary arteriovenous malformations: confirmation of
hereditary hemorrhagic telangiectasia in all cases. Journal of
Pediatrics 2007;151(3):299–306.
9Embolisation for pulmonary arteriovenous malformation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Dakeishi 2002
Dakeishi M, Shioya T, Wada Y, Shindo T, Otaka K, Manabe
M, Nozaki J, Inoue S, Koizumi A. Genetic epidemiology of
hereditary hemorrhagic telangiectasia in a local community
in the northern part of Japan. Human Mutation 2002;19
(2):140-8.
Faughnan 2000
Faughnan ME, Lui YW, Wirth JA, Pugash RA, Redelmeier
DA, Hyland RH, et al.Diffuse pulmonary arteriovenous
malformations: characteristics and prognosis. Chest 2000;
117(1):31–8.
Faughnan 2004
Faughnan ME, Thabet A, Mei-Zahav M, Colombo M,
Maclusky I, Hyland RH, et al.Pulmonary arteriovenous
malformations in children: Outcomes of transcatheter
embolotherapy. Journal of Pediatrics 2004;145(6):826–31.
Ferro 2007
Ferro C, Rossi UG, Bovio G, Seitun S, Rossi GA.
Percutaneous transcatheter embolization of a large
pulmonary arteriovenous fistula with an Amplatzer vascular
plug. Cardiovascular and Interventional Radiology 2007;30
(2):328–31.
Gallione 2004
Gallione CJ, Repetto GM, Legius E, Rustgi AK, Schelley
SL, Tejpar S, Mitchell G, Drouin E, Westermann CJ,
Marchuk D. A combined syndrome of juvenile polyposis
and hereditary haemorrhagic telangiectasia associated with
mutations in MADH4 (SMAD4). Lancet 2004;363(9412):
852–9.
Govani 2009
Govani FS, Shovlin CL. Hereditary haemorrhagic
telangiectasia: a clinical and scientific review. European
Journal of Human Genetics 2009;17(7):860–71.
Hannan 1989
Hannan EL, O’Donnell JF, Kilburn H Jr, Bernard HR,
Yazici A. Investigation of the relationship between volume
and mortality for surgical procedures performed in New
York State hospitals. JAMA 1989;262(4):503–10.
Higgins 2011
Higgins JPT, Green S (editors). Cochrane Handbook for
Systematic Reviews of Interventions Version 5.1 [updated
March 2011]. The Cochrane Collaboration, 2011.
Available from www.cochrane-handbook.org.
Khurshid 2002
Khurshid I, Downie GH. Pulmonary arteriovenous
malformation. Postgraduate Medical Journal 2002;78(918):
191–7.
Kjeldsen 1999
Kjeldsen AD, Vase P, Green A. Hereditary haemorrhagic
telangiectasia: a population-based study of prevalence and
mortality in Danish patients. Journal of Internal Medicine
1999;245(1):31–9.
Lee 1997
Lee DW, White RI Jr, Egglin TK, Pollak JS, Fayad
PB, Wirth JA, et al.Embolotherapy of large pulmonary
arteriovenous malformations: long-term results. Annals of
Thoracic Surgery 1997;64(4):930–40.
Mager 2004
Mager JJ, Overtoom TT, Blauw H, Lammers JW,
Westermann CJ. Embolotherapy of pulmonary
arteriovenous malformations: long-term results in 112
patients. Journal of Vascular and Interventional Radiology
2004;15(5):451–6.
Mathis 2012
Mathis S, Dupuis-Girod S, Plauchu H, Giroud M,
Barroso B, Ly KH, et al.Cerebral abscesses in hereditary
haemorrhagic telangiectasia: a clinical and microbiological
evaluation. Clinical Neurology and Neurosurgery 2012;114
(3):235–40.
Pierucci 2008
Pierucci P, Murphy J, Henderson KJ, Chyun DA, White
RI Jr. New definition and natural history of patients with
diffuse pulmonary arteriovenous malformations: twenty-
seven-year experience. Chest 2008;133(3):653–61.
Post 2006
Post MC, Thijs V, Schonewille WJ, Budts W, Snijder RJ,
Plokker HW, et al.Embolization of pulmonary arteriovenous
malformations and decrease in prevalence of migraine.
Neurology 2006;66(2):202–5.
Prasad 2004
Prasad V, Chan RP, Faughnan ME. Embolotherapy of
pulmonary arteriovenous malformations: efficacy of
platinum versus stainless steel coils. Journal of Vascular and
Interventional Radiology 2004;15(2 Pt 1):153–60.
Remy 1992
Remy J, Remy-Jardin M, Wattinne L, Deffontaines C.
Pulmonary arteriovenous malformations: evaluation with
CT of the chest before and after treatment. Radiology 1992;
182(3):809–16.
Remy 1994
Remy J, Remy-Jardin M, Giraud F, Wattinne
L. Angioarchitectureof pulmonary arteriovenous
malformations:clinical utility of 3D helical CT. Radiology
1994;191(3):657-64.
Remy-Jardin 2006
Remy-Jardin M, Dumont P, Brillet PY, Dupuis P, Duhamel
A, Remy J. Pulmonary arteriovenous malformations treated
with embolotherapy: helical CT evaluation of long-term
effectiveness after 2-21-year follow-up. Radiology 2006;239
(2):576–85.
Sabbà 2006
Sabbà C, Pasculli G, Suppressa P, D’Ovidio F, Lenato GM,
Resta F, et al.Life expectancy in patients with hereditary
haemorrhagic telangiectasia. QJM: An International Journal
of Medicine 2006;99(5):327–34.
Sagara 1998
Sagara K, Miyazono N, Inoue H, Ueno K, Nishida H,
Nakajo M. Recanalization after coil embolotherapy of
pulmonary arteriovenous malformations: study of long-
10Embolisation for pulmonary arteriovenous malformation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
term outcome and mechanism for recanalization. American
Journal of Roentgenology 1998;170(3):727–30.
Saluja 1999
Saluja S, Sitko I, Lee DW, Pollak J, White RI Jr.
Embolotherapy of pulmonary arteriovenous malformations
with detachable balloons: long-term durability and efficacy.
Journal of Vascular and Interventional Radiology 1999;10(7):
883–9.
Shovlin 2000
Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME,
Hyland RH, Westermann CJ, et al.Diagnostic criteria for
hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber
syndrome). American Journal of Medical Genetics 2000;91
(1):66–7.
Shovlin 2008c
Shovlin CL, Sodhi V, McCarthy A, Lasjaunias P, Jackson JE,
Sheppard MN. Estimates of maternal risks of pregnancy for
women with hereditary haemorrhagic telangiectasia (Osler-
Weber-Rendu syndrome): suggested approach for obstetric
services. BJOG: An International Journal of Obstetrics and
Gynaecology 2008;115(8):1108–15.
Shovlin 2010
Shovlin CL, Jackson JE. Pulmonary arteriovenous
malformations and other pulmonary vascular abnormalities.
In: Mason, Broaddus, Martin, Schraufnagel, Murray,
Nadel editor(s). Murray and Nadel’s Textbook of Respiratory
Medicine, 5th Edition. Pennsylvania: Elsevier-Saunders,
2010.
Swanson 1999
Swanson KL, Prakash UB, Stanson AW. Pulmonary
arteriovenous fistulas: Mayo Clinic experience, 1982-1997.
Mayo Clinic Proceedings 1999;74(7):671–80.
White 1983
White RI Jr, Mitchell SE, Barth KH, Kaufman SL,
Kadir S, Chang R, et al.Angioarchitecture of pulmonary
arteriovenous malformations: an important consideration
before embolotherapy. American Journal of Roentgenology
1983;140(4):681–6.
White 1988
White RI Jr, Lynch-Nyhan A, Terry P, Buescher PC,
Farmlett EJ, Charnas L, et al.Pulmonary arteriovenous
malformations: techniques and long-term outcome of
embolotherapy. Radiology 1988;169(3):663–9.
White 2007
White RI Jr. Pulmonary Arteriovenous Malformations:
How Do I Embolize?. Techniques in Vascular and
Interventional Radiology 2007;10(4):283–90.
References to other published versions of this review
Hsu 2010
Hsu CCT, Kwan GNC, Thompson SA, van Driel ML.
Embolisation therapy for pulmonary arteriovenous
malformations. Cochrane Database of Systematic Reviews
2010, Issue 5. [DOI: 10.1002/14651858.CD008017.pub2]
∗ Indicates the major publication for the study
11Embolisation for pulmonary arteriovenous malformation (Review)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Dutton 1995 Prospective case series of 53 participants with PAVMs treated with coil embolisation
Gupta 2002 Prospective case series of 66 consecutive individuals, 225 PAVMs were occluded by coil embolisation
Haitjema 1995 Prospective case series of 32 individuals, 92 PAVMs were treated by coil embolisation
Lacombe 2009 Prospective case series of 39 individuals previously identified to have bilateral PAVMs. 681 PAVMs were occluded
by embolisation. 238 PAVMs were treated using the peripheral blood flow redistribution technique
Liu 2010 Prospective study of 23 patients with symptomatic PAVMs underwent endovascular embolization; 7 cases were
associated with HHT. During the embolization, microcoils were applied in 6 cases and standard steel coils were
used in 17 cases
Pollak 1994 Prospective study of 35 individuals, 96 PAVMs, underwent embolisation with detachable silicone balloon, coil or
combination
Pollak 2006 Prospective study of 155 individuals, 415 PAVMs underwent embolisation with balloon, coil or combination of
both
Shovlin 2008a Prospective study of 323 consecutive individuals with PAVMs (n = 219) and/or HHT (n = 305) was performed.
Anderson-Gill models assessed constant and time dependent potential predictive variables for stroke/abscess, and
rate reduction by PAVMs embolisation
Shovlin 2008b Prospective study of 143 individuals, 4 individuals were excluded from the study due to severe pulmonary hyper-
tension, underwent embolisation and measurement of pulmonary artery pressure
CT: computed tomography
HHT: hereditary haemorrhagic telangiectasia
PAVMs: pulmonary arterial malformations
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. Search Strategy for the Cochrane Library (to 09 Feb 2012)
ID Search
#1 pulmonary near (arteriovenous malformation*)
#2 pulmonary near (arteriovenus fistula)
#3 pulmonary near avm
#4 pulmonary near (a-v malformation)
#5 pavm
#6 (#1 OR #2 OR #3 OR #4 OR #5)
Appendix 2. Ovid MEDLINE(R) and Ovid OLDMEDLINE(R) 1948 to present (09 Feb 2012) with
Daily Update Search Strategy:
#1 exp Arteriovenous Malformations/ 21933
#2 arteriovenous malformation$.mp. [mp=title, original title, ab-
stract, name of substance word, subject heading word]
13697
#3 arteriovenus fistula.mp. [mp=title, original title, abstract, name
of substance word, subject heading word]
2
#4 avm.mp. [mp=title, original title, abstract, name of substance
word, subject heading word]
2494
#5 a-v malformation.mp. [mp=title, original title, abstract, name
of substance word, subject heading word]
41
#6 4 or 1 or 3 or 2 or 5 23615
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(Continued)
#7 pulmonary.mp. adj4 (avm.mp. or exp Arteriovenous Malfor-
mations/ or arteriovenus fistula.mp. or arteriovenous malfor-
mation$.mp. or a-v malformation.mp.) [mp=title, original ti-
tle, abstract, name of substance word, subject heading word]
2556
#8 PAVM.mp. [mp=title, original title, abstract, name of sub-
stance word, subject heading word]
145
#9 8 or 7 2565
#10 exp Embolization, Therapeutic/ 20416
#11 emboli#ation.mp. [mp=title, original title, abstract, name of
substance word, subject heading word]
29651
#12 11 or 10 31188
#13 9 and 12 530
#14 randomized controlled trial.pt. 280487
#15 controlled clinical trial.pt. 80543
#16 randomized.ab. 189298
#17 placebo.ab. 115470
#18 drug therapy.fs. 1347511
#19 randomly.ab. 137122
#20 trial.ab. 196159
#21 groups.ab. 936463
#22 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 2468635
#23 (animals not (humans and animals)).sh. 3350294
#24 22 not 23 2092778
#25 24 and 13 21
#26 from 25 keep 1-21 21
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WH A T ’ S N E W
Last assessed as up-to-date: 6 June 2012.
Date Event Description
6 June 2012 New citation required but conclusions have not changed As no new studies have been included, the conclusions of
this review have not changed
6 June 2012 New search has been performed A search of the CFGD Group’s registers and MEDLINE
did not identify any new references which were potentially
eligible for inclusion in this review. One additional refer-
ence was added to the list of excluded studies (Liu 2010).
H I S T O R Y
Protocol first published: Issue 4, 2009
Review first published: Issue 5, 2010
C O N T R I B U T I O N S O F A U T H O R S
The original review was written by Charlie Chia-Tsong Hsu (CC-TH) and Gigi Nga Chi Kwan (GNCK) with comments from Shane
Anthony Thompson (SAT). Mieke L van Driel (MLvD) provided support with the methodological aspects of the review. All authors
contributed to drafting the protocol and the review and agreed on the final version.
At the first update of the review (2012), Hannah Evans-Barnes joined the review team. All authors contributed to updating the review
and agreed on the final version.
D E C L A R A T I O N S O F I N T E R E S T
None Known.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Following peer review comments at draft review stage it was decided to extend the scope of the review to include a comparison of
different embolisation devices.
Helical computer tomography (CT) pulmonary angiogram and helical CT without contrast media with three-dimensional reconstruc-
tion is a reliable tool for assessment of PAVMs prior to embolization and in the follow-up period. These outcome measures included
in the outcome measure in the 2012 updated review (Remy 1994; Remy-Jardin 2006).
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